Cardiff Oncology Inc reports results for the quarter ended in September - Earnings Summary

Cardiff Oncology

04/11/2021 21:35

* Cardiff Oncology Inc  CRDF.OQ  reported a quarterly adjusted
loss of 17 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 17 cents per share.
* Revenue fell 36.8% to $86.00 thousand from a year ago; 
analysts expected $30.00 thousand. 
* Cardiff Oncology Inc's reported EPS for the quarter was a loss
of 17 cents​.
* The mean earnings estimate of analysts had fallen by
about 4.6% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Cardiff Oncology Inc shares had fallen by 8.4% this
quarter and lost 66.1% so far this year.
* The company reported a quarterly loss of $6.92 million.
* Wall Street's median 12-month price target for Cardiff
Oncology Inc is $25.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 4 at 09:35 p.m.
 ​All figures in US dollars unless otherwise stated